論文・技術情報追加のお知らせ

1. Safety assessment of ambrisentan based on the FDA Adverse Event Reporting System.

FAERSを用いたアンブリセンタンの市販後安全性と心臓事象解析。

対象DB：FAERS

2. Real-world evidence on gadoteridol safety: A 20-year FAERS database study revealing critical adverse reaction patterns.

ガドテリドール投与に伴う有害事象に関する20年間のFAERS解析。

対象DB：FAERS

3. Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis.

CDK4/6阻害薬3種における腎有害事象プロファイルの比較解析。

対象DB：FAERS

4. Pharmacovigilance signal detection of rilonacept using FAERS with exploratory Mendelian randomization analysis.

リロナセプトのFAERS不均衡分析とメンデル無作為化による検証。

対象DB：FAERS

5. Serious and Non-serious Hepatitis Reports in the U.S. Vaccine Adverse Event Reporting System, 1990-2026: A Cross-Sectional Analysis.

VAERSデータに基づくワクチン接種後肝炎報告の重症度別解析。

対象DB：FAERS,VAERS

6. Age-stratified safety signal mining of ADHD medications in pediatric populations using the FAERS database (2014-2024): a pharmacovigilance study using multi-method disproportionality analysis.

小児ADHD治療薬の年齢層別不均衡分析と副作用シグナル検出。

対象DB：FAERS

7. Unsupervised machine learning for multi-system adverse event pattern detection in pharmacovigilance: A proof-of-concept analysis of fluoroquinolone reports in FAERS.

教師なし機械学習を用いたニューキノロン系多臓器有害事象の解析。

対象DB：CVAR,FAERS

8. Post-Marketing Safety of the Menin Inhibitor Revumenib: A Bayesian Disproportionality Analysis of a National Database.

メニン阻害薬レブメニブの市販後安全性に関する不均衡分析。

対象DB：FAERS

9. Sex-stratified disproportionality signals of adverse events with allopurinol and febuxostat: a retrospective pharmacovigilance analysis of FAERS and EudraVigilance.

アロプリノールとフェブキソスタットの性差に着目した副作用解析。

対象DB：EudraVigilance,FAERS

10. Peripheral and central nervous system toxicities of Bruton tyrosine kinase Inhibitors: a real-world pharmacovigilance study.

BTK阻害薬に伴う末梢・中枢神経系毒性のリアルワールド解析。

対象DB：FAERS

11. Temporal changes in auditory adverse event reporting in the U.S. vaccine adverse event reporting system associated with the COVID-19 vaccine rollout: an interrupted time series analysis with negative control evaluation.

COVID-19ワクチン導入に伴う聴覚障害報告の時系列変化分析。

対象DB：FAERS,VAERS

12. Haematological toxicity associated with antineoplastic drugs: a pharmacovigilance analysis based on the FDA adverse event reporting system database.

FAERSを用いた抗悪性腫瘍薬関連血液毒性の不均衡分析調査。

対象DB：FAERS

13. Male sexual dysfunction associated with TNF-alpha inhibitors: an indication-stratified global pharmacovigilance analysis.

TNF-α阻害薬関連男性性機能障害の適応症層別国際不均衡分析。

対象DB：FAERS

14. Mechanism-based reporting patterns of infection-related adverse events with systemic psoriasis therapies in FAERS.

乾癬全身療法薬における作用機序別の感染症関連有害事象解析。

対象DB：FAERS,KAERS

15. Multinational pharmacovigilance assessment of drug-associated esophageal ulceration and perforation: evidence from FAERS, JADER, and Canada Vigilance.

3か国の自発報告データを用いた薬剤性食道潰瘍・穿孔の比較解析。

対象DB：CVAR,FAERS,JADER

16. Sex Differences in Sentiment-Scored Vocabulary Patterns in VAERS Free-Text Narratives of Four Major Vaccine Categories.

VAERSテキストにおけるワクチン関連語彙パターンの性差解析。

対象DB：FAERS,VAERS

17. Cardiotoxicity of macrolide antibiotics: a pharmacovigilance study integrating FAERS and JADER databases.

マクロライド系抗菌薬の心毒性プロファイルに関する二国間DB解析。

対象DB：FAERS,JADER

18. Sex- and age-specific musculoskeletal adverse events of isotretinoin: disproportionality analysis of the FAERS database combined with a clinical case series.

イソトレチノイン投与に伴う骨格筋系有害事象の性・年齢層別解析。

対象DB：FAERS

19. Beyond disproportionality: systematic prioritization of actionable levothyroxine safety signals in FAERS.

レボチロキシン関連副作用シグナルの体系的優先順位付けと評価。

対象DB：FAERS

20. Neurological and hematological safety profiles of GSK-3beta inhibitors: insights from multi-database pharmacovigilance and experimental validation.

GSK-3β阻害薬の神経・血液系安全性に関する多角的不均衡分析。

対象DB：JADER

21. Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues.

チルゼパチドの治療不全および使用問題に関する欧州DB不均衡分析。

対象DB：EudraVigilance

22. The Value of Time-to-Onset for Signal Validation: Experience from the Reporting of COVID-19 Vaccines and Glomerular Diseases in VigiBase.

COVID-19ワクチン後の糸球体疾患における発現時期の評価。

対象DB：VigiBase

23. Immune-related adverse events with mogamulizumab in cutaneous T-cell lymphoma: A multicentre study.

皮膚T細胞リンパ腫でのモガムリズマブによる免疫関連有害事象調査。

対象DB：VigiBase

24. Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force "Dermatology for Cancer Patients" and pharmacovigilance analysis.

サシツズマブ ゴビテカンに伴う皮膚有害事象の国際調査と解析。

対象DB：FPVD,VigiBase

25. Trends in Denture Insurance Claims and Their Association With Socioeconomic Indicators and Population Aging in Japan.

日本の義歯保険請求件数の経時的推移と社会経済指標・高齢化の解析。

対象DB：NDB

26. Treatment patterns, intensive treatment, and hospitalization-related burden of juvenile generalized myasthenia gravis in Japan: a retrospective cohort study using a hospital-based claims database.

日本における小児全身型重症筋無力症の治療パターンと入院負担。

対象DB：MDV

27. Association between depression and the development of end-stage kidney disease in people with diabetes: A population-based cohort study.

糖尿病患者におけるうつ病と末期腎不全発症リスクの関連性解析。

対象DB：CPRD

28. Changes in healthcare use and cost associated with referrals to social prescribing link workers in England: a matched case-control cohort study.

英国における社会的処方リンクワーカー紹介に伴う医療利用変化。

対象DB：CPRD

29. Seasonal variation in day-to-day blood pressure variability: large-scale within-individual home blood pressure data.

大規模家庭血圧データを用いた日内・日間血圧変動の季節性解析。

対象DB：DeSC

30. Estimated small dense low-density lipoprotein cholesterol in predicting atherosclerotic cardiovascular disease: Longitudinal evidence from over 1 million Japanese adults.

sdLDL-C推定値による動脈硬化性心血管疾患予測の縦断的検証。

対象DB：DeSC

31. Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer.

CDK4/6阻害薬投与転移性乳がん患者の医療費構造解析。

対象DB：DeSC